Product Name | Amifostine |
Description |
HIF-1α activator |
Purity | >98% |
CAS No. | 20537-88-6 |
Molecular Formula | C5H15N2O3PS |
Molecular Weight | 214.22 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Activator |
Solubility | Soluble in water |
Source | Synthetic |
Appearance | White Solid |
SMILES | C(CN)CNCCSP(=O)(O)O |
InChI | InChI=1S/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10) |
InChIKey | JKOQGQFVAUAYPM-UHFFFAOYSA-N |
Safety Phrases |
Classification: Harmful. May be harmful if inhaled, swallowed or absorbed through skin. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection Hazard Phrases: H302 |
Cite This Product | Amifostine (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-210) |
Alternative Names | S-{2-[(3-Aminopropyl)amino]ethyl} dihydrogen phosphorothioate |
Research Areas | Apoptosis, Cancer |
PubChem ID | 2141 |
Scientific Background | Amifostine is a cytoprotective agent used to mitigate the side effects of chemotherapy and radiotherapy. In neuroscience, it is studied for its ability to accelerate DNA repair, inhibit apoptosis, and modulate oxidative stress responses. Its protective effects on neural tissues make it a candidate for reducing neurotoxicity in therapeutic interventions. |
References |
1. Kouvaris J.R., Kouloulias V.E., Blahos L.J. (2007) Oncologist. 12(6): 738-747. 2. Amifostine: BC Cancer Agency. 2006-03-01. |
Reviews
There are no reviews yet.